CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
CEP-701drug
Likely dose
CEP-701 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00494585
NCT00494585Phase 2Completed
CompareCT.gov

Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis

M.D. Anderson Cancer Center·interventional·Posted Jun 29, 2007·Updated Jun 25, 2012

In Brief

A Phase 2 clinical trial evaluating CEP-701 for Leukemia and Myelofibrosis. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find out if CEP-701 can help control myelofibrosis (MF). The safety of CEP-701 will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myelofibrosis
CountriesUnited States
CollaboratorsCephalon

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 29, 2007
Enrollment StartJun 1, 2007
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 19.0 years ago

Interventions

CEP-701drug

80 mg orally twice a day for 30 days